Several studies assessed the correlation of radiolabeled cetuximab uptake with EGFR expression to predict response to anti-EGFR therapies in HNSCC (67, 266–268), showing a clear tumor visualization in almost all patients (8/9) in phase I clinical trial (111). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.